During the government shutdown, public health experts talked political and monetary hurdles, and fostering community amid ...
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025.Total revenues comprise product sales and royalty, contract and other revenues.While higher ...
A slew of National Institutes of Health grant terminations in the spring left affected Northwestern researchers with few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results